Addressing intra-tumoral heterogeneity and therapy resistance

In the last several years, our appreciation of intra-tumoral heterogeneity has greatly increased due to accumulating evidence for the co-existence of genetically and epigenetically divergent cancer cells residing in different microenvironments within a tumor. Herein, we review recent literature discussing intra-tumoral heterogeneity in the context of therapy resistance mechanisms at the genetic, epigenetic and microenvironmental levels. We illustrate the influence of tumor microenvironment on therapy resistance and epigenetic states of cancer cells by highlighting the role of cancer stem cells in therapy resistance. We also summarize different strategies that have been employed to address various resistance mechanisms at genetic, epigenetic, and microenvironmental levels in preclinical and clinical studies. We propose that future personalized cancer therapy design needs to incorporate dynamic and comprehensive analyses of tumor heterogeneity landscape and multi-dimensional mechanisms of therapy resistance.

[1]  Paul A. Wiggins,et al.  Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state , 2011, Proceedings of the National Academy of Sciences.

[2]  Karen H. Vousden,et al.  Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.

[3]  Michael J. Ziller,et al.  Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. , 2014, Cancer cell.

[4]  R. Jain,et al.  Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors , 2011, Proceedings of the National Academy of Sciences.

[5]  D. Pinkel,et al.  The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis , 1999, Cell.

[6]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[7]  Jing Yuan,et al.  Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma , 2010, Science Translational Medicine.

[8]  B. Rosen,et al.  Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation , 2013, Proceedings of the National Academy of Sciences.

[9]  Yong Sun,et al.  An IL6-STAT3 loop mediates resistance to PI3K inhibitors by inducing epithelial-mesenchymal transition and cancer stem cell expansion in human breast cancer cells. , 2014, Biochemical and biophysical research communications.

[10]  Kristiina Vuori,et al.  Integrin Signaling in Cancer Cell Survival and Chemoresistance , 2012, Chemotherapy research and practice.

[11]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[12]  K. Ramos,et al.  The promise and failures of epigenetic therapies for cancer treatment. , 2014, Cancer treatment reviews.

[13]  K. Ueno,et al.  The c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells , 2015, Journal of cellular and molecular medicine.

[14]  Shan Jiang,et al.  Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer , 2014, Cell.

[15]  Joseph Rosenbluh,et al.  KRAS and YAP1 Converge to Regulate EMT and Tumor Survival , 2014, Cell.

[16]  T. Keck,et al.  ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat , 2015, EMBO molecular medicine.

[17]  E. Plimack,et al.  AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. , 2013, The oncologist.

[18]  M. Israel,et al.  Cancer stem cells are enriched in the side population cells in a mouse model of glioma. , 2008, Cancer research.

[19]  Jacques Haiech,et al.  Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy , 2016, Stem cells international.

[20]  E. Bahassi,et al.  Targeting DNA repair mechanisms in cancer. , 2013, Pharmacology & therapeutics.

[21]  Dong-Sup Lee,et al.  Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas , 2008, Laboratory Investigation.

[22]  P. Timpson,et al.  FAK signaling in human cancer as a target for therapeutics. , 2015, Pharmacology & therapeutics.

[23]  A. Shaw,et al.  Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine , 2015, Clinical Cancer Research.

[24]  Guoyu Pan,et al.  HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review) , 2014, Oncology letters.

[25]  D. Matei,et al.  Epigenetic targeting of ovarian cancer stem cells. , 2014, Cancer research.

[26]  J. Machiels,et al.  A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.

[27]  S. Neelapu,et al.  Cancer immunotherapy: Strategies for personalization and combinatorial approaches , 2015, Molecular oncology.

[28]  G. Alexiou,et al.  The role of heat shock proteins in cancer. , 2015, Cancer letters.

[29]  C. Garlanda,et al.  Tumor associated macrophages and neutrophils in tumor progression , 2013, Journal of cellular physiology.

[30]  S. Bicciato,et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.

[31]  G. Semenza,et al.  Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells , 2014, Proceedings of the National Academy of Sciences.

[32]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[33]  M. Biffoni,et al.  TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells , 2014, Oncogene.

[34]  Marek Ancukiewicz,et al.  Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer , 2015, Proceedings of the National Academy of Sciences.

[35]  D. Matei,et al.  The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer , 2014, Clinical Cancer Research.

[36]  Frederick Luk,et al.  Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy? , 2014, Drug Metabolism And Disposition.

[37]  S. Baylin,et al.  Harnessing the potential of epigenetic therapy to target solid tumors. , 2014, The Journal of clinical investigation.

[38]  W. Carroll,et al.  Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. , 2012, Blood.

[39]  Kornelia Polyak,et al.  Cellular heterogeneity and molecular evolution in cancer. , 2013, Annual review of pathology.

[40]  J. Bollyky,et al.  4-Methylumbelliferone Treatment and Hyaluronan Inhibition as a Therapeutic Strategy in Inflammation, Autoimmunity, and Cancer , 2015, Front. Immunol..

[41]  P. Angenendt,et al.  Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies , 2015, Oncotarget.

[42]  Martin E. Gleave,et al.  Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.

[43]  Gordon B Mills,et al.  Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. , 2012, Cancer cell.

[44]  D. Matei,et al.  Epigenetic resensitization to platinum in ovarian cancer. , 2012, Cancer research.

[45]  Jane Fridlyand,et al.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.

[46]  Robin L. Jones,et al.  Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. , 2014, Cell reports.

[47]  Alfonso Valencia,et al.  Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment , 2014, Clinical Cancer Research.

[48]  K. Kinzler,et al.  Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells , 2014, Journal of Immunotherapy for Cancer.

[49]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Neve,et al.  AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. , 2014, Cancer research.

[51]  M. Wirth,et al.  Aldehyde Dehydrogenase Is Regulated by β-Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. , 2015, Cancer research.

[52]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[53]  C. Rudin,et al.  Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma , 2009, Science.

[54]  Antonio Marchetti,et al.  The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies , 2015, Nature Genetics.

[55]  You Han Bae,et al.  Tumor heterogeneity and its implication for drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[56]  S. Pyndiah,et al.  c-MYC Suppresses BIN1 to Release Poly(ADP-Ribose) Polymerase 1: A Mechanism by Which Cancer Cells Acquire Cisplatin Resistance , 2011, Science Signaling.

[57]  R. Bronson,et al.  Epigenetic states of cells of origin and tumor evolution drive tumor-initiating cell phenotype and tumor heterogeneity. , 2014, Cancer research.

[58]  D. Ellison,et al.  Molecular Heterogeneity in a Patient-Derived Glioblastoma Xenoline Is Regulated by Different Cancer Stem Cell Populations , 2015, PloS one.

[59]  E. Thompson,et al.  Targeting EMT in cancer: opportunities for pharmacological intervention. , 2014, Trends in pharmacological sciences.

[60]  C. Shapiro,et al.  AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. , 2014, Cancer research.

[61]  Song Gao,et al.  Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma , 2014, Oncotarget.

[62]  M. Kohno,et al.  Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross‐resistance to a wide range of DNA‐damaging drugs , 2008, Cancer science.

[63]  Wei Li,et al.  RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors. , 2015, Cancer research.

[64]  C. Rudin,et al.  Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. , 2015, Cancer cell.

[65]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[66]  M. Maitland,et al.  Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Eugene S. Kim,et al.  G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation. , 2015, Cancer research.

[68]  J. Settleman,et al.  Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition , 2014, Oncotarget.

[69]  Obi L. Griffith,et al.  Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor , 2014, Nature.

[70]  Mathias J Friedrich,et al.  CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice , 2015, Proceedings of the National Academy of Sciences.

[71]  O. Wiestler,et al.  Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins , 2008, Oncogene.

[72]  D. Raha,et al.  The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. , 2014, Cancer research.

[73]  G. Semenza,et al.  Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype , 2014, Oncotarget.

[74]  Ho-June Lee,et al.  Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. , 2014, Cancer cell.

[75]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[76]  P. Carmeliet,et al.  Tumor vessel normalization by chloroquine independent of autophagy. , 2014, Cancer cell.

[77]  C. Rudin,et al.  Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. , 2013, Cancer cell.

[78]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[79]  R. Jain.  Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  T. Bowman,et al.  NF-κB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth , 2013, Molecular Cancer Research.

[81]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[82]  E. Reed,et al.  ALDH1A1 Maintains Ovarian Cancer Stem Cell-Like Properties by Altered Regulation of Cell Cycle Checkpoint and DNA Repair Network Signaling , 2014, PloS one.

[83]  Stephen A. Sastra,et al.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.

[84]  V. P. Collins,et al.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.

[85]  L. Sequist,et al.  Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[86]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[87]  Michael F. Clarke,et al.  Phenotypic characterization of human colorectal cancer stem cells , 2007, Proceedings of the National Academy of Sciences.

[88]  R. Bernards,et al.  PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  R. McLendon,et al.  Acidic stress promotes a glioma stem cell phenotype , 2011, Cell Death and Differentiation.

[90]  Suzanne F. Jones,et al.  Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[91]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[93]  H. Drexler,et al.  BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance , 2011, Journal of hematology & oncology.

[94]  T. Beißbarth,et al.  STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo , 2014, International journal of cancer.

[95]  Valerie M. Weaver,et al.  Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors , 2015, Molecular biology of the cell.

[96]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[97]  S. Clarke,et al.  Cancer-related inflammation and treatment effectiveness. , 2014, The Lancet. Oncology.

[98]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[99]  Se Hoon Kim,et al.  Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. , 2013, Cancer cell.

[100]  N. Tunariu,et al.  Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration , 2015, Clinical Cancer Research.

[101]  C. Paweletz,et al.  Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA , 2014, Clinical Cancer Research.

[102]  G. Mills,et al.  Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies , 2015, Clinical Cancer Research.

[103]  S. Ha,et al.  Direct endothelial junction restoration results in significant tumor vascular normalization and metastasis inhibition in mice , 2014, Oncotarget.

[104]  M. Carcangiu,et al.  Maspin influences response to doxorubicin by changing the tumor microenvironment organization , 2014, International journal of cancer.

[105]  W. Wilson,et al.  Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.

[106]  Amos Tanay,et al.  Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. , 2014, Cell reports.

[107]  S. Niclou,et al.  Critical appraisal of the side population assay in stem cell and cancer stem cell research. , 2011, Cell stem cell.

[108]  R. Amaravadi,et al.  Emerging strategies to effectively target autophagy in cancer , 2016, Oncogene.

[109]  M. Kester,et al.  Formation and role of exosomes in cancer , 2014, Cellular and Molecular Life Sciences.

[110]  Beatriz Bellosillo,et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[111]  Hanlee P. Ji,et al.  Pan-cancer analysis of the extent and consequences of intratumor heterogeneity , 2015, Nature Medicine.

[112]  U. Pastorino,et al.  Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[113]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[114]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[115]  S. Peters,et al.  BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[116]  Qiu-ying Liu,et al.  Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway , 2015, Molecular Cancer.

[117]  M. Karin,et al.  IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. , 2014, Seminars in immunology.

[118]  R. Weinberg,et al.  Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.

[119]  M. Rebucci,et al.  Molecular aspects of cancer cell resistance to chemotherapy. , 2013, Biochemical pharmacology.

[120]  Peter Ulz,et al.  Circulating tumor DNA as a liquid biopsy for cancer. , 2015, Clinical chemistry.

[121]  Hongmei Yu,et al.  Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cells , 2011, Proceedings of the National Academy of Sciences.

[122]  R. Bristow,et al.  HDAC inhibitor confers radiosensitivity to prostate stem-like cells , 2013, British Journal of Cancer.

[123]  H. Gogas,et al.  Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials. , 2014, Cancer letters.

[124]  J. Reis-Filho,et al.  Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival , 2016, Oncotarget.

[125]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[126]  N. McGranahan,et al.  Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.

[127]  C. Cordon-Cardo,et al.  Targeting cancer stem cells to suppress acquired chemotherapy resistance , 2014, Oncogene.

[128]  L. Mariani,et al.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment , 2009, Proceedings of the National Academy of Sciences.

[129]  Dihua Yu,et al.  Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. , 2012, Trends in pharmacological sciences.

[130]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[131]  Charles Swanton,et al.  Translational Implications of Tumor Heterogeneity , 2015, Clinical Cancer Research.

[132]  Allison Hills,et al.  Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. , 2015, Clinical chemistry.

[133]  Carlos Caldas,et al.  The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.

[134]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[135]  J. Herman,et al.  Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. , 2011, Cancer discovery.

[136]  N. Cordes,et al.  Focal adhesion signaling and therapy resistance in cancer. , 2015, Seminars in cancer biology.

[137]  R. Vandenbroucke,et al.  Is there new hope for therapeutic matrix metalloproteinase inhibition? , 2014, Nature Reviews Drug Discovery.

[138]  D. Capper,et al.  Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation , 2009, Acta Neuropathologica.

[139]  P. Fisher,et al.  Targeting the Bcl-2 family for cancer therapy , 2013, Expert opinion on therapeutic targets.

[140]  W. Parson,et al.  The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics , 2014, Oncotarget.

[141]  Robert A. Weinberg,et al.  Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity , 2013, Cell.

[142]  Nita Ahuja,et al.  Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. , 2012, Cancer cell.

[143]  Lei Mu,et al.  Fibroblast-Derived Exosomes Contribute to Chemoresistance through Priming Cancer Stem Cells in Colorectal Cancer , 2015, PloS one.

[144]  W. El-Deiry,et al.  Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. , 2014, Current drug targets.

[145]  Jorge Sabbaga,et al.  Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice , 2015, Oncotarget.

[146]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[147]  F. Hirsch,et al.  Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  P. Harari,et al.  p53 modulates acquired resistance to EGFR inhibitors and radiation. , 2011, Cancer research.

[149]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[150]  Akio Ohta,et al.  Immunological mechanisms of the antitumor effects of supplemental oxygenation , 2015, Science Translational Medicine.

[151]  A. Hochhaus,et al.  Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients , 2015, Annals of Hematology.

[152]  Tzong-Shiue Yu,et al.  A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .